HK1203232A1 - 生物標誌物及其用途 - Google Patents

生物標誌物及其用途

Info

Publication number
HK1203232A1
HK1203232A1 HK15103699.1A HK15103699A HK1203232A1 HK 1203232 A1 HK1203232 A1 HK 1203232A1 HK 15103699 A HK15103699 A HK 15103699A HK 1203232 A1 HK1203232 A1 HK 1203232A1
Authority
HK
Hong Kong
Prior art keywords
biomarker
Prior art date
Application number
HK15103699.1A
Other languages
English (en)
Inventor
金．蘇姍妮．米德伍德
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201121280A external-priority patent/GB201121280D0/en
Priority claimed from GBGB1214806.0A external-priority patent/GB201214806D0/en
Application filed by Isis Innovation filed Critical Isis Innovation
Publication of HK1203232A1 publication Critical patent/HK1203232A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15103699.1A 2011-12-12 2015-04-15 生物標誌物及其用途 HK1203232A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201121280A GB201121280D0 (en) 2011-12-12 2011-12-12 Biomarker
GBGB1214806.0A GB201214806D0 (en) 2012-08-20 2012-08-20 Biomarker
PCT/GB2012/053104 WO2013088140A2 (en) 2011-12-12 2012-12-12 Biomarker and use thereof

Publications (1)

Publication Number Publication Date
HK1203232A1 true HK1203232A1 (zh) 2015-10-23

Family

ID=47561655

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103699.1A HK1203232A1 (zh) 2011-12-12 2015-04-15 生物標誌物及其用途

Country Status (10)

Country Link
US (1) US20140322211A1 (zh)
EP (1) EP2791686B1 (zh)
JP (1) JP6158825B2 (zh)
KR (1) KR20140109956A (zh)
CN (1) CN104105967B (zh)
BR (1) BR112014014295A2 (zh)
CA (1) CA2894746A1 (zh)
HK (1) HK1203232A1 (zh)
IN (1) IN2014MN01372A (zh)
WO (1) WO2013088140A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400521D0 (en) * 2014-01-13 2014-02-26 Isis Innovation Biomarker and uses thereof
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
ES2352180T3 (es) * 2002-02-26 2011-02-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anticuerpo monoclonal de anti-tenascina humana.
US20060115862A1 (en) * 2004-11-17 2006-06-01 Duke University Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
KR100958840B1 (ko) * 2007-08-28 2010-05-24 단국대학교 산학협력단 항－테나신 c 펩타이드 및 그의 용도
JP2011501147A (ja) * 2007-10-22 2011-01-06 ノバルティス・フォルシュングスシュティフトゥング・ツヴァイクニーダーラッスング・フリードリッヒ・ミーシェー・インスティトゥート・フォー・バイオメディカル・リサーチ 結腸癌のバイオマーカーとしてのテネイシン−ｗの使用
FR2930036B1 (fr) * 2008-04-11 2010-05-07 Assist Publ Hopitaux De Paris Procede de diagnostic d'une hypertension arterielle pulmonaire.
GB0904355D0 (en) * 2009-03-13 2009-04-29 Imp Innovations Ltd Biological materials and uses thereof
JP6099560B2 (ja) * 2010-05-12 2017-03-22 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド イヌの炎症を診断、抑制および予防し、炎症状態を緩和するための方法
JP5360922B2 (ja) * 2011-08-03 2013-12-04 国立大学法人山口大学 新規虚血マーカー及びこれを用いた虚血状態の検出方法

Also Published As

Publication number Publication date
EP2791686B1 (en) 2017-02-15
JP2015503106A (ja) 2015-01-29
EP2791686A2 (en) 2014-10-22
WO2013088140A2 (en) 2013-06-20
CN104105967A (zh) 2014-10-15
IN2014MN01372A (zh) 2015-04-17
CN104105967B (zh) 2017-03-08
BR112014014295A2 (pt) 2017-06-13
WO2013088140A3 (en) 2013-08-08
US20140322211A1 (en) 2014-10-30
CA2894746A1 (en) 2013-06-20
JP6158825B2 (ja) 2017-07-05
KR20140109956A (ko) 2014-09-16

Similar Documents

Publication Publication Date Title
HUS2100012I1 (hu) 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók
IL233051B (en) Anti-phf-tau antibodies and uses thereof
EP2670866A4 (en) BIOMARKERS AND METHODS OF USE
EP2742154A4 (en) BIOMARKER COMPOSITIONS AND METHODS
EP2721179A4 (en) BIOMARKER COMPOSITIONS AND ASSOCIATED METHODS
IL229844B (en) Anti-psgl-1 antibodies and their use
GB201111705D0 (en) Compounds and their use
HK1191034A1 (zh) -羧烷基耳他汀類及其應用
GB201110783D0 (en) Methods and uses
EP3701800C0 (en) USE
IL231082A0 (en) Pyrimido-pyridazinone compounds and their use
EP2819749A4 (en) BIOMARKERS ASSOCIATED WITH AUTISM AND USES THEREOF
EP2688588A4 (en) FAST AND LONG-TERM IMMUNOLOGICAL THERAPEUTIC
GB201116774D0 (en) Uses and methods
EP2697386A4 (en) DESIGN AND USE OF PEPDUCINE
EP2716359A4 (en) COMPLEX AND USES THEREOF
GB201211158D0 (en) Biomarkers and uses thereof
GB201114448D0 (en) Compounds and their use
EP2693879A4 (en) MIGRASTATINES AND THEIR USES
HK1203232A1 (zh) 生物標誌物及其用途
HK1198587A1 (zh) 異噻唑並吡啶- -甲酰胺和它們作為藥物的用途
GB201108490D0 (en) Methods and uses
GB201117881D0 (en) Biomarkers and uses thereof
GB201114341D0 (en) Reagent and use
IL230868A0 (en) Biomarker preparations and methods

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211216